Merck Stock Sees Record Call Options Trading Amid Vaccine Success

Merck & Co., Inc.'s stock saw unusually large options trading on Wednesday. Investors purchased 68,587 call options, a significant increase of 188% compared to the average volume of 23,838 call options.

This buying activity follows positive news for Merck, as its melanoma skin cancer vaccine has met its primary goal in a recent trial. The vaccine demonstrated improved results compared to Keytruda alone and could potentially expand Keytruda's long-term growth opportunity.

Analysts are awaiting complete trial data, including the magnitude and durability of the benefit, safety results, regulatory filings, and potential commercialization details. Some analysts have already set new price targets for Merck, with Daiwa Securities Group raising its target to $143.00 and BMO Capital Markets lifting its target from $135.00 to $142.00.

Merck & Co., Inc.'s stock price has been rising, reaching a 52-week high of $151.82. The company's market capitalization is approximately $372.16 billion, with a price-to-earnings ratio of 120.51 and a PEG ratio of 5.86.